Natco Pharma Q2: profits under pressure despite revenue growth

reported a 23% year-on-year drop in Q2FY26 net profit to ₹518 crore, even as revenue rose slightly to ₹1,463 crore, reflecting margin pressure and possibly fewer one-time or high-margin profits versus the previous year. This decline comes amid a strong operational EBITDA (estimated at ₹474 crore, with margins near 41%), but higher input costs, product mix normalization, or elevated R&D and SG&A may have weighed on net profitability.​ Key takeaways Topline up, profit down: Revenue growth did not translate proportionally into the bottom line, highlighting margin compression or prior-year base effects.​ Industry lens: Pharma sector faces continued volatility from pricing pressure in the U.S., raw material inflation, and regulatory scrutiny; firms like Natco must offset this by scaling new launches and specialty portfolios.​ Market reaction: The result echoes sector trends of margin headwinds despite steady revenues; investors will be watching for cost control, pipeline visibility, and USFDA/regulatory updates to drive H2 sentiment.​ Watch ahead Upcoming launches, international market growth, and sustained cost management will be critical in restoring profit momentum for Natco, especially as sectoral headwinds remain into FY26. No Recommendations Source: The Hindu